Edding Genor Group Holdings Limited

Genor Biopharma Holdings Limited operates as a biopharmaceutical enterprise, concentrating its efforts on the research, development, and commercialization of therapeutic agents for oncology and autoimmune disorders, both within China and globally. Its key investigational medicines include GB242, an infliximab (Remicade) biosimilar. This drug is purposed for the treatment of various conditions such as rheumatoid arthritis, ankylosing spondylitis, psoriasis, adult ulcerative colitis, adult and pediatric Crohn's disease, and fistulizing Crohn's disease. Another prominent candidate is GB491 (lerociclib), an oral CDK4/6 inhibitor currently undergoing Phase III clinical trials for hormone receptor-positive (HR+)/HER2- breast cancer. Additionally, GB492, a stimulator of interferon genes (STING) agonist, is in Phase 1/2 clinical development, with expectations of synergistic effects when combined with GB226 for solid tumor treatment. The company's pipeline also encompasses GB221, a HER2 monoclonal antibody (mAb) designed to mimic trastuzumab (Herceptin); geptanolimab (GB226), a novel PD-1 mAb; GB223, a receptor activator of nuclear factor-B Ligand (RANKL) mAb, which is in Phase I clinical trials; and GB261, also in Phase I clinical trials for B-cell non-Hodgkin Lymphoma. Furthermore, its product candidates in clinical trials for cancer treatment include GB262, GB264, GB265, and GB266. Originally named JHBP (CY) Holdings Limited, the company adopted its current moniker, Genor Biopharma Holdings Limited, in June 2021. Founded in 2007, the firm maintains its headquarters in Shanghai, China.

Industry

Biotechnology

Sector

Healthcare

Headquarters

CN

CEO

Xin Ni

Listed since

Oct 7, 2020

Employees

1,545